Trevi Therapeutics (TRVI) Non-Current Debt (2020 - 2022)

Trevi Therapeutics' Non-Current Debt history runs 3 years deep, the most recent figure standing at $2.2 million for Q4 2022.

• In Q4 2022, Non-Current Debt fell 75.14% year-over-year to $2.2 million; the TTM figure through Dec 2022 stood at $2.2 million (down 75.14% YoY), while the FY2022 annual figure was $2.2 million, down 75.14% from the prior year.
• Non-Current Debt for Q4 2022 stood at $2.2 million, down from $3.8 million in the prior quarter.
• The five-year high for Non-Current Debt was $14.0 million in Q4 2020, with the low at $2.2 million in Q4 2022.
• The 3-year median for Non-Current Debt is $9.4 million (2021), against an average of $9.1 million.
• The sharpest annual moves came in 2021 and 2022: Non-Current Debt slipped 25.75% in 2021, then tumbled 75.14% in 2022.
• Trevi Therapeutics' Non-Current Debt stood at $14.0 million in 2020, then slumped by 38.0% to $8.7 million in 2021, then sank by 75.14% to $2.2 million in 2022.
• Business Quant data shows TRVI's Non-Current Debt at $2.2 million in Q4 2022, $3.8 million in Q3 2022, and $5.4 million in Q2 2022.